Home/Immatics Biotechnologies/Cedrik Britten, M.D.
CB

Cedrik Britten, M.D.

Chief Medical Officer

Immatics Biotechnologies

Therapeutic Areas

Immatics Biotechnologies Pipeline

DrugIndicationPhase
IMA203PRAME-positive solid tumorsPhase 1/2
IMA203CD8PRAME-positive solid tumorsPhase 1/2
IMA402PRAME-positive solid tumorsPhase 1/2
IMA204Undisclosed solid tumorsPhase 1